Skip to main content
SpringerLink
Log in

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reinhart KL, Gloer JB, Hughes RG, Renis HE, Mcgovrern JP, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li LH: Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 212:933–955, 1981

    Google Scholar 

  2. Dorr FA, Kuhn JG, Phillips J, Von Hoff DD: Phase I clinical and pharmakokinetic investigation of Didemnin B, a cyclic depsipeptide. Eur. J. Cancer Clin. Oncol. 24:1699–1706, 1988

    Google Scholar 

  3. Miller AB, Hoogstrated B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    Google Scholar 

  4. Taylor S, Piston B, Stevens RL, Crawford ED: Phase II Trial of Didemnin B in advanced adenocarcinoma of the kidney: Southwest Oncology Study Group Study. Proc Am Soc Clin Oncol 8:564, 1989 (abstract)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Robert Motzer, Howard Scher, Dean Bajorin, Cora Sternberg & George J. Bosl

  2. Department of Medicine, Cornell University Medical College, New York, NY, USA

    Robert Motzer, Howard Scher, Dean Bajorin, Cora Sternberg & George J. Bosl

Authors
  1. Robert Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard Scher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dean Bajorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cora Sternberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. George J. Bosl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Motzer, R., Scher, H., Bajorin, D. et al. Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Invest New Drugs 8, 391–392 (1990). https://doi.org/10.1007/BF00198598

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00198598

Key words

Search

Navigation